Iovance Biotherapeutics, Inc. (IOVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IOVA Stock Price Chart Interactive Chart >
IOVA Price/Volume Stats
| Current price | $7.96 | 52-week high | $18.73 |
| Prev. close | $7.95 | 52-week low | $5.42 |
| Day low | $7.90 | Volume | 4,476,743 |
| Day high | $8.19 | Avg. volume | 5,241,885 |
| 50-day MA | $6.62 | Dividend yield | N/A |
| 200-day MA | $10.11 | Market Cap | 1.26B |
Iovance Biotherapeutics, Inc. (IOVA) Company Bio
Iovance Biotherapeutics, formerly known as Lion Biotechnologies, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company was founded in 2007 and is based in Woodland Hills, California.
Latest IOVA News From Around the Web
Below are the latest news stories about IOVANCE BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate IOVA as an investment opportunity.
Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock a better investment at this time?Currently, Iovance Biotherapeutics Inc.’s (IOVA) stock is trading at $7.34, marking a gain of 4.93% from last night’s close. At this price, the stock is -60.78% below its 52-week high of $18.73 and 35.52% above its 52-week low of $5.42. Based on the past 30-day period, the stock price is -0.34% below the high and […] |
Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023. |
Iovance Biotherapeutics Acquires Clinigen''s IL-2 Product For Upfront £166.7MFull story available on Benzinga.com |
Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million23 January 2023 Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million The deal includes a £41.7 million milestone payment and double-digit Proleukin® global sales royalties Clinigen Limited (‘Clinigen'') (‘the Company''), the global pharmaceutical services company, has entered into an agreement to divest Proleukin® (interleukin-2 (aldesleukin)), to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) (‘Iovance''), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte (TIL) and peripheral-blood lymphocyte (PBL)). Terms of the agreement include an upfront payment of £166.7 million, a £41.7 million milestone payment upon first approval of lifileucel in advanced melanoma, and double-digit Proleukin® global sales r... |
Foolproof stocks: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA 5.90%), QuantumScape Corporation (NYSE:QS 3.36%)IOVA has seen its SMA50 which is now -0.22%. In looking the SMA 200 we see that the stock has seen a -36.45%. QS has seen its SMA50 which is … The post Foolproof stocks: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA 5.90%), QuantumScape Corporation (NYSE:QS 3.36%) appeared first on Stocks Equity . |
IOVA Price Returns
| 1-mo | 24.57% |
| 3-mo | -10.56% |
| 6-mo | -36.52% |
| 1-year | -52.19% |
| 3-year | -63.39% |
| 5-year | -51.76% |
| YTD | 24.57% |
| 2022 | -66.53% |
| 2021 | -58.86% |
| 2020 | 67.63% |
| 2019 | 212.77% |
| 2018 | 10.63% |
Loading social stream, please wait...